West (WST) Q3 2026 Earnings Call Transcript

West Pharmaceutical Services reported Q3 2026 net sales of $874.5 million, up 8.7% reported and 11.9% organically, while adjusted diluted EPS rose 35.7% to $2.66 and exceeded the prior guidance midpoint by $0.47. Gross margin expanded 310 bps to 39.7%, and the company raised full-year sales guidance to $3.41–$3.42 billion and adjusted EPS guidance to $9.38–$9.48; HVP Components grew 20.3% organically and represented 53% of sales. West also raised its dividend 18% to $0.26 per share and repurchased $685 million of shares year to date. The SmartDose 3.5 divestiture is expected to create an approximately 290-bps headwind to reported growth next year, while new HVP finishing capacity is expected to come online in 18–24 months.

Analysis

The key upside is not simply GLP-1 exposure: HVP upgrades and biologics create a second growth engine that could make WST less dependent on any single drug class. If regulatory tightening spreads beyond Europe, component upgrades can raise value per unit without requiring equivalent volume growth. That supports mix and incremental margins—but the quarter’s margin step-up should not be extrapolated as a new run rate: mix, pricing and factory leverage all contributed, while management itself did not call it a floor.

Near term, the higher guide supports sentiment, but the 2027 comparison is less clean. The SmartDose divestiture creates a reported-growth drag, and Q4 growth is guided below Q3’s pace; reported deceleration could obscure continued organic HVP strength and trigger multiple compression. Separately, lower 2026 capex alongside announced capacity expansion may reflect timing, not lower investment needs. With nine-month free cash flow down and substantial repurchases, watch working-capital conversion and whether buybacks compete with high-return finishing capacity investment.

Over 6–18 months, the thesis depends on upgrade projects converting to orders, U.S. regulatory guidance translating into customer action, and new finishing capacity arriving on schedule. GLP-1 concentration is meaningful, but management’s cited high-teens non-GLP-1 HVP growth is a useful diversification check. A reversal would be upgrade delays, capacity bottlenecks, or a sharp slowdown in HVP demand; verify project conversion, organic growth excluding SmartDose, and cash conversion before paying for the long-duration growth narrative.

Key Decisions for Investors

• Favor a staged long in WST on post-earnings consolidation rather than chasing a gap higher. The thesis is durable HVP mix/upgrade growth, not a repeat of this quarter’s margin expansion. Reassess if HVP organic growth materially slows or operating-margin gains reverse.
• For the next 1–3 months, distinguish reported deceleration from underlying demand: track organic sales excluding SmartDose and HVP Components growth. Treat the 2027 reported-growth headwind as a known comparison issue, not by itself as evidence of demand deterioration.
• Watch U.S. regulatory guidance and customer upgrade conversion as 6–18 month catalysts. Raise conviction only if announced projects become orders and capacity plans remain on schedule; slower conversion or service constraints would falsify the upgrade-led thesis.
• Monitor working capital, free-cash-flow conversion and capital allocation alongside buybacks. If receivables and inventory remain elevated while capacity investment ramps, reduce confidence in shareholder returns as a near-term support.